Feb 19 |
Harrow's Drug Iheezo Is Off To A Great Start
|
Feb 15 |
Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products
|
Feb 5 |
Harrow: Hedge Downside Risk With The 11.5% Yielding Baby Bonds
|
Jan 30 |
Harrow: Temporary Disruption In Stock Price Creates Excellent Opportunity
|
Jan 29 |
Harrow Announces New Appointments to its Board of Directors
|
Jan 11 |
Harrow says dry eye drug Vevye now available in US
|
Jan 11 |
Harrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease
|
Jan 3 |
Melt Pharmaceuticals Provides Corporate Update
|
Jan 3 |
Harrow Partners with Leading Healthcare Market Access Technology Platforms
|
Nov 29 |
Harrow Completes Transfer of the TRIESENCE® New Drug Application
|